Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lifastuzumab vedotin
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lifastuzumab vedotin is an experimental antibody-drug conjugate (ADC) developed for the treatment of cancer. It consists of a humanized monoclonal antibody targeting SLC34A2 (also known as sodium-dependent phosphate transport protein 2B or NaPi2b), which is highly expressed in certain tumors such as ovarian and lung cancers. The antibody is conjugated via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) linker to the cytotoxic payload monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization that disrupts mitosis and induces apoptosis in targeted cells. Lifastuzumab vedotin was primarily investigated for platinum-resistant ovarian cancer and non-small cell lung cancer but development was discontinued after phase II trials failed to meet primary endpoints[4][5][6].
- Other names
- Anti-NaPi2bAnti-NaPi-2bAnti-NaPi 2bNaPi2b-ADCNaPi-2b-ADCNaPi 2b-ADCNaPi3bNaPi-3bNaPi 3b
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lifastuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lifastuzumab vedotin.